DZ3453A1 - Compose lactame - Google Patents

Compose lactame

Info

Publication number
DZ3453A1
DZ3453A1 DZ013453A DZ013453A DZ3453A1 DZ 3453 A1 DZ3453 A1 DZ 3453A1 DZ 013453 A DZ013453 A DZ 013453A DZ 013453 A DZ013453 A DZ 013453A DZ 3453 A1 DZ3453 A1 DZ 3453A1
Authority
DZ
Algeria
Prior art keywords
lactame
compound
lactame compound
Prior art date
Application number
DZ013453A
Other languages
English (en)
Inventor
James Edmund Audia
Varghese John
Lee H Latimer
Stacey Leigh Mcdaniel
Jeffrey Scott Nissen
Eugene D Thorsett
Jay S Tung
Original Assignee
Lilly Co Eli
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli, Elan Pharm Inc filed Critical Lilly Co Eli
Application granted granted Critical
Publication of DZ3453A1 publication Critical patent/DZ3453A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
DZ013453A 2000-11-17 2001-11-05 Compose lactame DZ3453A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24955200P 2000-11-17 2000-11-17
PCT/US2001/027799 WO2002047671A2 (fr) 2000-11-17 2001-11-05 Composé de lactam

Publications (1)

Publication Number Publication Date
DZ3453A1 true DZ3453A1 (fr) 2002-06-20

Family

ID=22943982

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ013453A DZ3453A1 (fr) 2000-11-17 2001-11-05 Compose lactame

Country Status (33)

Country Link
US (1) US20050261495A1 (fr)
EP (1) EP1341531B1 (fr)
JP (1) JP4116437B2 (fr)
KR (1) KR100819679B1 (fr)
CN (1) CN1486184A (fr)
AR (1) AR035927A1 (fr)
AU (2) AU2002243192B2 (fr)
BR (1) BR0115427A (fr)
CA (1) CA2427227C (fr)
CY (1) CY1106366T1 (fr)
CZ (1) CZ20031351A3 (fr)
DE (1) DE60126132T2 (fr)
DK (1) DK1341531T3 (fr)
DZ (1) DZ3453A1 (fr)
EA (1) EA005954B1 (fr)
EC (1) ECSP034600A (fr)
ES (1) ES2278804T3 (fr)
HR (1) HRP20030383B1 (fr)
HU (1) HU228117B1 (fr)
IL (2) IL155960A0 (fr)
MX (1) MXPA03004292A (fr)
MY (1) MY134559A (fr)
NO (1) NO324324B1 (fr)
NZ (1) NZ525854A (fr)
PE (1) PE20020802A1 (fr)
PL (1) PL212199B1 (fr)
PT (1) PT1341531E (fr)
SI (1) SI1341531T1 (fr)
SK (1) SK288065B6 (fr)
TW (1) TWI305204B (fr)
UA (1) UA74849C2 (fr)
WO (1) WO2002047671A2 (fr)
ZA (1) ZA200303789B (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468365B2 (en) 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
CA2603320A1 (fr) 2005-04-08 2006-10-19 Daiichi Sankyo Company, Limited Derive de pyridylmethylsulfone
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
EP1985615A4 (fr) 2006-01-31 2011-12-14 Api Corp Procédé de production de benzazépinone
CA2676715A1 (fr) 2007-02-12 2008-08-21 Merck & Co., Inc. Derives de piperazine pour le traitement de la maladie d'alzheimer et des conditions apparentees
CL2008002060A1 (es) * 2007-07-16 2008-11-21 Wyeth Corp Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.
KR101136260B1 (ko) 2007-08-14 2012-04-19 일라이 릴리 앤드 캄파니 감마-세크레타제 억제제로서의 아제핀 유도체
TW200920362A (en) 2007-09-11 2009-05-16 Daiichi Sankyo Co Ltd Alkylsulfone derivatives
CN101945853B (zh) 2007-12-21 2014-08-20 配体药物公司 选择性雄激素受体调节剂(sarm)及其应用
WO2009128057A2 (fr) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Produits psycho-pharmaceutiques
EP2413932A4 (fr) 2009-04-01 2012-09-19 Merck Sharp & Dohme Inhibiteurs de l'activité akt
CA2777043C (fr) 2009-10-14 2015-12-15 Schering Corporation Piperidines substituees qui accroissent l'activite de p53, et utilisations de ces composes
EP2584903B1 (fr) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Nouveaux composés hétérocycliques utilisés comme inhibiteurs de erk
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
EP2613782B1 (fr) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012040444A2 (fr) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Traitement de patients présentant un début de maladie d'alzheimer
WO2012058210A1 (fr) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. INHIBITION FACILITÉE PAR L'INTERFÉRENCE D'ARN DE L'EXPRESSION D'UN GÈNE AU MOYEN D'ACIDES NUCLÉIQUES INTERFÉRENTS COURTS (siNA)
WO2012087772A1 (fr) 2010-12-21 2012-06-28 Schering Corporation Dérivés d'indazole utiles en tant qu'inhibiteurs de erk
EP2770987B1 (fr) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
CN102690231B (zh) * 2012-04-11 2014-07-09 南京友杰医药科技有限公司 治疗阿尔茨海默病潜在药物司马西特的合成方法
EP3919620A1 (fr) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Compositions d'acide nucléique interférent court (sina)
EP2892506B1 (fr) 2012-09-07 2021-11-03 Massachusetts Eye & Ear Infirmary Traitement de la perte auditive avec l'inhibiteur de la gamma-secrétase ly411575
CA2884309A1 (fr) 2012-09-07 2014-03-13 Massachusetts Eye And Ear Infirmary Methodes et compositions pour la regeneration des cellules de cheveux et/ou des cellules de soutien a partir de cellules cochleaires differenciees ou de cellules utriculaires differenciees par modulation de l'activite de notch et de c-myc
CA2882950A1 (fr) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Nouveaux composes inhibiteurs de erk
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2014100065A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Imidazopyridines substituées en tant qu'inhibiteurs de hdm2
WO2014120748A1 (fr) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. Purines 2,6,7,8-substituées utilisées en tant qu'inhibiteurs de hdm2
EP2987496B1 (fr) 2013-04-19 2018-08-08 National University Corporation Okayama University Agent de traitement des troubles cognitifs, basé sur la protéine bêta-amyloïde, agent thérapeutique contre la maladie d'alzheimer et procédé de traitement et procédé d'analyse pathologique correspondants
WO2015034925A1 (fr) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Polynucléotides circulaires
EP3613418A1 (fr) 2014-01-17 2020-02-26 Ligand Pharmaceuticals, Inc. Procédés et compositions de modulation des niveaux d'hormones
EP3212773B1 (fr) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Administration efficace de molécules thérapeutiques en direction de cellules de l'oreille interne
KR102362222B1 (ko) 2016-05-16 2022-02-11 더 제너럴 하스피탈 코포레이션 폐 상피 공학에서 인간 기도 줄기 세포
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
EP3706742B1 (fr) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
WO2019094312A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
CA3108388A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020033285A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
AU2020257397B2 (en) 2019-04-19 2026-02-26 Ligand Pharmaceuticals Inc. Crystalline forms and methods of producing crystalline forms of a compound
EP4076460B1 (fr) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC Dérivés de 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidine] en tant qu'inhibiteurs de prmt5 pour le traitement du cancer
EP4076459B1 (fr) 2019-12-17 2026-04-29 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
ES3022307T3 (en) 2019-12-17 2025-05-28 Merck Sharp & Dohme Llc Prmt5 inhibitors
ES3074517T3 (en) 2019-12-17 2026-07-21 Merck Sharp & Dohme Llc 4-(3,4-dihydroisoquinolin-2(1h)-yl)-3-hydroxypiperidine derivatives as prmt5 inhibitors for the treatment of cancer and sickle cell disease
CN120225528A (zh) 2022-09-02 2025-06-27 默沙东有限责任公司 依喜替康衍生的拓扑异构酶-1抑制剂药物组合物及其用途
KR20250079227A (ko) 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도
KR20250116773A (ko) 2022-12-14 2025-08-01 머크 샤프 앤드 돔 엘엘씨 아우리스타틴 링커-페이로드, 제약 조성물, 및 그의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA9711537B (en) * 1996-12-23 1998-06-25 Athena Neurosciences Inc Eli L Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting ß-amyloid peptide release and/or its synthesis by use of such compounds.
AU4707999A (en) * 1998-06-22 2000-01-10 Elan Pharmaceuticals, Inc. Compounds for inhibiting beta-amyloid peptide release and/or its synthesis
AU1569501A (en) * 1999-11-09 2001-06-06 Eli Lilly And Company Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis
DE60135489D1 (de) * 2000-11-17 2008-10-02 Lilly Co Eli Lactam dipeptid und dessen verwendung zur inhibierung der beta-amyloid peptid frisetzung
UA74849C2 (en) * 2000-11-17 2006-02-15 Lilly Co Eli Lactam
UA77165C2 (en) * 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition

Also Published As

Publication number Publication date
AR035927A1 (es) 2004-07-28
JP2004517090A (ja) 2004-06-10
AU2002243192B2 (en) 2006-07-20
NO20032236L (no) 2003-07-10
HUP0301842A3 (en) 2010-03-29
UA74849C2 (en) 2006-02-15
NZ525854A (en) 2004-06-25
EA200300580A1 (ru) 2003-10-30
HUP0301842A2 (hu) 2003-09-29
SI1341531T1 (sl) 2007-06-30
HK1059731A1 (en) 2004-07-16
EA005954B1 (ru) 2005-08-25
MY134559A (en) 2007-12-31
WO2002047671A2 (fr) 2002-06-20
IL155960A (en) 2009-06-15
PL362688A1 (en) 2004-11-02
PE20020802A1 (es) 2002-09-10
US20050261495A1 (en) 2005-11-24
JP4116437B2 (ja) 2008-07-09
CN1486184A (zh) 2004-03-31
SK5592003A3 (en) 2003-12-02
KR20030051846A (ko) 2003-06-25
MXPA03004292A (es) 2004-02-12
DE60126132D1 (de) 2007-03-08
CA2427227C (fr) 2010-08-17
ZA200303789B (en) 2004-08-16
ECSP034600A (es) 2003-06-25
WO2002047671A3 (fr) 2003-03-06
BR0115427A (pt) 2003-10-07
CZ20031351A3 (cs) 2003-11-12
KR100819679B1 (ko) 2008-04-04
DK1341531T3 (da) 2007-05-14
ES2278804T3 (es) 2007-08-16
TWI305204B (en) 2009-01-11
EP1341531A2 (fr) 2003-09-10
NO324324B1 (no) 2007-09-24
HRP20030383B1 (hr) 2007-12-31
CA2427227A1 (fr) 2002-06-20
HRP20030383A2 (en) 2005-10-31
IL155960A0 (en) 2003-12-23
AU4319202A (en) 2002-06-24
EP1341531B1 (fr) 2007-01-17
DE60126132T2 (de) 2007-10-18
HU228117B1 (en) 2012-11-28
PL212199B1 (pl) 2012-08-31
SK288065B6 (sk) 2013-04-03
CY1106366T1 (el) 2011-10-12
PT1341531E (pt) 2007-04-30
NO20032236D0 (no) 2003-05-16

Similar Documents

Publication Publication Date Title
DK1432329T3 (da) Tandbörste
ATE513491T1 (de) Zahnbürste
DK1265511T3 (da) Tandbørste
NO20032236D0 (no) Laktamforbindelse
NO20024042L (no) Aryl-fusjonerte azapolysykliske forbindelser
FI20010780A0 (fi) Parannetut koostumukset
DZ3454A1 (fr) Compose lactame
DE60112774D1 (de) Reibungsarme zahnbürste
ID29755A (id) Senyawa-senyawa organosilikon
DE60131345D1 (de) Kommutatormotor
NO20024322D0 (no) Sekvens
PL369886A1 (pl) Arylo-skondensowane związki azapolicykliczne
DE60210813D1 (de) Zahnbürste
TR200100070A3 (tr) Bilesim
NO20031893D0 (no) Pendelagn
FR2833982B1 (fr) Plaque de platre
ES1051991Y (es) Cepillo
NO20021026D0 (no) Ny forbindelse F-15078
NO20033586L (no) Tannbörste
SE0004680D0 (sv) New compound
SE0103802D0 (sv) Novel compound
FI5191U1 (fi) Hammasharja
FI20012564A0 (fi) Hammasharja
SE0101394D0 (sv) Borstanordning
PT9700T (pt) Divisoria extensivel